Outlook Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OTLK research report →
Range $1.6 – $4
Price Chart
About the company
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials.
- CEO
- Robert Charles Jahr
- IPO
- 2016
- Employees
- 17
- HQ
- Iselin, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep downtrend, trading well below its 200-day moving average of 0.6603 and 50-day average of 0.5636. It is still far from the 52-week high of 2.5375, though the rebound from the 52-week low of 0.1611 shows a volatile base rather than a clean recovery.
Street sentiment is constructive but cautious: consensus is Buy with a 2.8 average target, and the latest changes included BTIG’s upgrade to Buy and H.C. Wainwright’s target raise to $1.60. The setup favors traders watching for follow-through, but the target range still sits well above the current share price.
The earnings profile is uneven, with 2 beats in the last 7 quarters and several recent misses, including a flat result on the latest reported quarter. Next-year EPS is still expected to improve to -0.12 from a -0.70 TTM loss, so shareholders should watch whether losses narrow and guidance holds.
Insiders have been net buyers, led by large open-market purchases from directors and the 10% owner, alongside several officer and director awards. The signal is supportive because the meaningful activity is mostly discretionary buying, while the award grants are compensation-related noise rather than fresh conviction.
Profitability remains weak, with ROA at -1.4317 and TTM EPS at -0.70, but operating margin is positive at 47.8184%. Revenue growth is still deeply negative at -99.4% year over year, and the balance sheet shows $8.1 million of cash against $30.2 million of debt, leaving net debt of $22.1 million.
As a clinical-stage biotech, OTLK trades on pipeline execution rather than current earnings power, so it screens cheaper than profitable peers but with far higher binary risk. The valuation remains distressed versus the sector, which fits a turnaround/speculative profile more than a quality-growth one.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $94.94M
- P/E
- -0.36
- Fwd P/E
- 1.24
- PEG
- 0.00
- P/S
- -83.93
- P/B
- -5.28
- EV/EBITDA
- -1.68
- Div Yield
- 0.00%
- Gross Margin
- 195.64%
- Op Margin
- 4783.05%
- Net Margin
- 5254.81%
- ROE
- 222.01%
- ROIC
- -343.68%
Latest fiscal year · YoY change
- Revenue
- $1.41M+0.0%
- Gross Profit
- $657.21K+0.0%
- Op Income
- $-67,061,666
- Net Income
- $-62,424,863+17.2%
- EPS
- $-1.79+55.9%
- OCF Growth
- +24.7%
- FCF Growth
- +24.7%
- 52W High
- $2.54
- 52W Low
- $0.16
- 50D MA
- $0.54
- 200D MA
- $0.66
- Beta
- 0.71
- RSI (14)
- 37
- Avg Volume
- 4.70M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Outlook Therapeutics said FDA approval of LYTENAVA turned it into a commercial-stage company, and management outlined a U.S. launch plan, first-year revenue ramp, and a long-term path to more than $500 million in peak U.S. sales by 2030.· August 14, 2026
- FDA approved LYTENAVA for wet AMD; management says it is the only FDA-approved ophthalmic bevacizumab formulation in the U.S.
- The company is targeting more than $500 million in peak annual U.S. sales by 2030, with upside if repackaged compounded bevacizumab is disrupted.
- First-year U.S. net revenue after launch is expected to be $50 million to $75 million, with Europe contributing about 10% to 15%.
- Cash was $11.2 million at June 30; post-quarter-end, the company announced a $55 million public offering expected to bring about $51.1 million in net proceeds.
- Launch build-out will include about 30 customer-facing commercial hires and about 20 field reimbursement hires, plus a permanent HCPCS code filing by end of the third quarter and an expected J-code in April next year.
For fiscal Q3 2026, Outlook reported adjusted net loss attributable to common stockholders of $10.9 million, or $0.09 per basic and diluted share, versus $15.8 million, or $0.44 per share, in fiscal Q3 2025. Management said the adjusted results exclude noncash and nonrecurring items, mainly changes in warrant and promissory note fair value and a debt extinguishment loss. As of June 30, cash and cash equivalents were $11.2 million. After quarter end, the company announced a $55 million common stock and warrant offering, with expected net proceeds of about $51.1 million, intended to fund the U.S. launch and general corporate purposes. Forward guidance called for first 12 months of U.S. launch net revenue of $50 million to $75 million, with Europe contributing 10% to 15% of that total; about 10% of first-year revenue is expected in the first 3 months and about 50% in the fourth quarter after launch. SG&A is expected to approximately double by the end of calendar 2026 and rise another 10% in calendar 2027, while R&D should remain relatively steady over the next 12 months.
Bob Jahr framed the FDA approval as transformational and said the company is now focused on converting that regulatory win into a disciplined commercial launch. He emphasized that LYTENAVA is aimed at the established repackaged bevacizumab market, not the branded anti-VEGF category, and argued that the product combines bevacizumab familiarity with FDA manufacturing and quality standards. His tone was confident but measured: he repeatedly described the launch plan as conservative, market-tested, and dependent on execution, access, and reimbursement.
Lawrence Kenyon highlighted the quarter’s adjusted net loss of $10.9 million, or $0.09 per share, and noted that cash was $11.2 million at June 30 before the subsequent financing. He said the $55 million offering, expected to yield about $51.1 million net, is meant to support the U.S. commercial launch and working capital needs. On operating expense, he guided SG&A to roughly double by the end of 2026 and then increase another 10% in 2027, while R&D should stay relatively steady as the prefilled syringe program advances.
Analysts focused on how much upside exists if compounded repackaged bevacizumab becomes less available, how LYTENAVA compares with biosimilars on pricing and access, and how patient out-of-pocket costs could affect adoption without the Good Days Foundation support. Management said disruption in the compounded market could add just under $300 million of upside to the $500 million 2030 base case, but not all of that would necessarily flow to LYTENAVA because some could go to biosimilars. Bob Jahr also said many Medicare and Medicare Advantage plans still require step therapy, that the company’s pricing work aims to keep out-of-pocket burdens manageable, and that early adopters appear to be a meaningful slice of retina physicians who already rely heavily on compounded bevacizumab.
The call’s bullish case is that Outlook now has an FDA-approved product in a large, established wet AMD market where bevacizumab is already widely used. Management believes roughly 1/3 of retina physicians could be early adopters and that LYTENAVA can win share by offering FDA oversight, product consistency, and practical reimbursement support. The company also pointed to a strong launch package: enough supply for launch, a focused commercial model, and a long-term revenue target with upside if market conditions change.
The main risks are reimbursement complexity, patient out-of-pocket costs, and heavy competition from compounded bevacizumab, biosimilars, and other anti-VEGF options. Management acknowledged that adoption may be slow until a permanent J-code is in place and that some payers still require step-through use of cheaper options first. Europe remains a tougher and lower-margin opportunity, with pricing pressure, tenders, and country-by-country reimbursement challenges limiting near-term progress.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.4%
- Shares Outstanding
- 243.45M
- Float Shares
- 212.68M
of shares held by institutions
79 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 8.98M | ▲ 4.60M |
| Marshall Wace, Llp | 8.02M | ▲ 6.04M |
| Ubs Group AG | 3.34M | ▲ 3.19M |
| Perceptive Advisors LLC | 3.14M | ▲ 3.14M |
| Geode Capital Management, LLC | 1.72M | ▲ 470.54K |
| Blackrock, Inc. | 1.67M | ▼ 804 |
| Vanguard Group Inc | 1.47M | ▲ 122.54K |
| Renaissance Technologies LLC | 1.12M | ▲ 1.12M |
| Vanguard Fiduciary Trust Co | 1.07M | ▲ 406.25K |
| Susquehanna International Group, Llp | 968.19K | ▲ 834.11K |
| Gilpin Wealth Management, LLC | 625.00K | ▲ 70.00K |
| State Street Corp | 569.70K | ▲ 29.90K |
Held by 25 ETFs
Biggest fund positions in OTLK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Lundquist Kevin Michael | other | 500,000 |
| Sep 1, 26 | Lundquist Kevin Michael | other | 0 |
| Aug 14, 26 | Jahr Robert Charles | buy | 151,515 |
| Aug 14, 26 | Jahr Robert Charles | buy | 151,515 |
| Aug 12, 26 | Sukhtian Ghiath M. | buy | 2,525,252 |
| Aug 12, 26 | Sukhtian Ghiath M. | buy | 2,525,252 |
| Aug 14, 26 | KENYON LAWRENCE A | buy | 101,010 |
| Aug 14, 26 | KENYON LAWRENCE A | buy | 101,010 |
| Jul 29, 26 | Sukhtian Faisal Ghiath | buy | 95,398 |
| Jul 21, 26 | KENYON LAWRENCE A | other | 210,078 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OTLK coverage
Recent articles, reports, and earnings notes.

OTLK insiders just bought $5.81 million. The dilution risk is still the trade
OTLK's $5.81 million insider buying is a real vote of confidence, but the company is still funding an approved product with fresh equity. A $55 million stock-and-warrant offering, a 600 million share authorization and ongoing losses keep dilution ahead of durable commercial proof.

OTLK's FDA win is now a dilution story
OTLK has a real FDA-approved product, but the shareholder-approved expansion to 600 million authorized shares makes dilution the dominant trade setup. The August offering shows that financing pressure survived the regulatory victory and is already reaching common holders.
Want a deeper read on OTLK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
This Outlook Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com · Nov 19
Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis
defenseworld.net · Oct 16
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
globenewswire.com · Oct 9
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
globenewswire.com · Oct 6
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
globenewswire.com · Oct 1
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
businesswire.com · Sep 22
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
defenseworld.net · Sep 16
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
globenewswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice